{
    "clinical_study": {
        "@rank": "98961", 
        "arm_group": {
            "arm_group_label": "131I-rituximab", 
            "arm_group_type": "Experimental", 
            "description": "131I-rituximab treatment interval at least 4 weeks up to maximum 6 cycles"
        }, 
        "brief_summary": {
            "textblock": "Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma in\n      Korea.  Although there is standard therapy, which is called 'R-CHOP', many obstacles to use\n      aggressive cytotoxic chemotherapeutic agents such as old age, poor performance status,\n      refractoriness, and relapsed disease still remains. So we investigate the efficacy of\n      radioimmunotherapy using 131I-rituximab in refractory or relapsed patients with DLBCL."
        }, 
        "brief_title": "A Phase II Study of 131I-rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)", 
        "completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Relapsed or Refractory Diffuse Large B Cell Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, B-Cell", 
                "Lymphoma, Large B-Cell, Diffuse"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed diffuse large B cell lymphoma Elderly (>65 years) or\n             medically ineligible to standard cytotoxic chemotherapy due to poor performance\n             status, or relapsed or refractory patients Eastern Cooperative Oncology Group\n             performance status \u2264 2, age\u2265 20 years Relapsed or refractory after autologous\n             hematopoietic stem cell transplantation (auto-HSCT) in young patients with good\n             performance status and indicated to high dose chemotherapy and auto-HSCT More than\n             one measurable lesion\n\n          -  More than 2cm sized lesion in conventional CT scan,\n\n          -  More than 1cm sized lesion in spiral CT or contrast-enhanced PET/CT Adequate renal\n             function (serum creatinine \u2264 2.0 mg/dl  or Ccr \u2265 60 ml/min) Adequate hepatic function\n             (serum bilirubin \u2264 2.0 mg/dl , AST/ALT \u2264 3 upper normal limit) Adequate bone marrow\n             reservoir (ANC \u22651,500/\u3395, platelet count\u2265 75,000/\u3395) patient who agree the purpose and\n             intention of this clinical trial\n\n        Exclusion Criteria:\n\n          -  recent (<5 years) history of other malignancy or unrecovered from the disease\n             (appropriately treated skin cancer and uterine cervix carcinoma in situ are excluded)\n\n               -  hemodynamically unstable due to the recent (<12 months) history of severe heart\n                  disease such as myocardial infarction\n\n               -  acute complications of severe lung or metabolic disease\n\n               -  Combined severe neurological or psychiatric disease Unrecovered from infection\n                  or other medical disease Recent (<30 days) history of enrollment of other\n                  clinical trial Pregnant or breast-feeding woman women of childbearing potential\n                  and men not employing adequate contraception at least for 1 year Previous\n                  history drug allergy to the content of 131I-rituximab Infection(sepsis,\n                  pneumonia, viral infection, etc) (inactivated hepatitis B carrier can be\n                  enrolled) Young patient with good performance status indicated to autologous\n                  hematopoietic stem cell transplantation irrespective of  the failure of 1st line\n                  chemotherapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 24, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01676558", 
            "org_study_id": "DLBCL_131I-rituximab RIT"
        }, 
        "intervention": {
            "arm_group_label": "131I-rituximab", 
            "intervention_name": "131I-rituximab", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Rituximab"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "diffuse large B cell lymphoma", 
            "radioimmunotherapy", 
            "131I-rituximab"
        ], 
        "lastchanged_date": "November 13, 2012", 
        "location": [
            {
                "contact": {
                    "last_name": "Hye Jin Kang, M.D."
                }, 
                "contact_backup": {
                    "last_name": "Dong-Yeop Shin, M.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences"
                }, 
                "investigator": [
                    {
                        "last_name": "Hye Jin Kang, M.D.", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Dong-Yeop Shin, M.D.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Sung Hyun Yang, M.D.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Im Il Na, M.D.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Hyo-Rak Lee, M.D.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Sang Moo Lim, M.D.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Chang Woon Choi, M.D.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Byung Il Kim, M.D.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Ilhan Im, M.D.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Seung Sook Lee, M.D.", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "139-706"
                    }, 
                    "name": "Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Study of 131I-rituximab for Elderly or Poor Performance Status Patients With Diffuse Large B Cell Lymphoma (DLBCL) or for Adult Patients With Relapsed or Refractory DLBCL", 
        "overall_contact": {
            "email": "mdhyejin@gmail.com", 
            "last_name": "Hye Jin Kang, M.D.", 
            "phone": "+82-2-970-1289"
        }, 
        "overall_contact_backup": {
            "email": "baramg@hanmail.net", 
            "last_name": "Dong-Yeop Shin, M.D.", 
            "phone": "+82-2-970-1246"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "International Working Group Response criteria", 
            "measure": "overall response rate", 
            "safety_issue": "No", 
            "time_frame": "up to 5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01676558"
        }, 
        "secondary_outcome": [
            {
                "measure": "Response duration", 
                "safety_issue": "No", 
                "time_frame": "up to 5 years"
            }, 
            {
                "measure": "progression free survival", 
                "safety_issue": "No", 
                "time_frame": "up to 5 years"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "up to 5 years"
            }, 
            {
                "description": "grading the adverse events using CTCAE version 4.03", 
                "measure": "Number of Adverse event", 
                "safety_issue": "Yes", 
                "time_frame": "up to 5 years"
            }
        ], 
        "source": "Korea Cancer Center Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Korea Cancer Center Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}